Pharmacogenetics of DNA repair gene polymorphisms in non-small-cell lung carcinoma patients on platinum-based chemotherapy

Zhang, L; Ma, Wei; Li, Y; Wu, Jin; Shi, Guangyue

doi:10.4238/2014.january.14.2

Cited by 23 publications

(15 citation statements)

References 23 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(2013)Asian (China)5438/1656 (30–73)III-IVDDP/CBP-basedORPCR-RFLP XRCC1 rs1799782, RRM1 rs12806698 96 Zhang, Y P. (2013)Asian (China)6238/2458 (37–72)NRDDP+NVB/TAX/GEM/PEMORDirect sequencing XPD rs13181 97 Zhou, G R. (2013)Asian (China)204120/8461 (45–75)NRDDP -basedORMALDI-TOF-MS XRCC1 rs25487 98 Huang, S. J. (2014)Asian (China)187124/63NRIIIA-IVPlatinum-basedOR, OSMALDI-TOF-MS ERCC1 rs11615 rs3212986, rs2298881 99 Zhang, L. (2014)Asian (China)375249/126NRIIIA-IVCBP+NVP+DDP, DDP+DOCOR, OS, PFSSequenom MassARRAY platform XPD rs13181 rs1799793 rs1052555 rs238406, XRCC1 rs25487 rs1799782 100 Jin, Z. Y. (2014)Asian (China)378297/8162.4 (36–78)I-IVDDP+GEM/DOC/NVP/TAXOR, OSPCR-RFLP XPG rs1047768 rs17655 XRCC1 rs25489, XRCC3 rs861539 101 Hu, W. (2014)Asian (China)277184/9363.1 (29–75)IIIA-IVPlatinum-basedOS, PFSPCR-RFLP XPG rs1047768 rs17655 rs2296147 rs873601 102 Peng, Y.…”

Section: Resultsmentioning

confidence: 99%

Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis

Tan

Qiu

Zhu

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Data regarding genetic polymorphisms and platinum-based chemotherapy (PBC) treatment outcomes in patients with NSCLC are published at a growing pace, but the results are inconsistent. This meta-analysis integrated eligible candidate genes to better evaluate the pharmacogenetics of PBC in NSCLC patients. Relevant studies were retrieved from PubMed, Chinese National Knowledge Infrastructure and WANFANG databases. A total of 111 articles comprising 18,196 subjects were included for this study. The associations of genetic polymorphisms with treatment outcomes of PBC including overall response rate (ORR), overall survival (OS) and progression-free survival (PFS) were determined by analyzing the relative risk (RR), hazard ration (HR), corresponding 95% confidence interval (CI). Eleven polymorphisms in 9 genes, including ERCC1 rs11615 (OS), rs3212986 (ORR), XPA rs1800975 (ORR), XPD rs1052555 (OS, PFS), rs13181 (OS, PFS), XPG rs2296147 (OS), XRCC1 rs1799782 (ORR), XRCC3 rs861539 (ORR), GSTP1 rs1695 (ORR), MTHFR rs1801133 (ORR) and MDR1 rs1045642 (ORR), were found significantly associated with PBC treatment outcomes. These variants were mainly involved in DNA repair (EXCC1, XPA, XPD, XPG, XRCC1 and XRCC3), drug influx and efflux (MDR1), metabolism and detoxification (GSTP1) and DNA synthesis (MTHFR), and might be considered as potential prognostic biomarkers for assessing objective response and progression risk in NSCLC patients receiving platinum-based regimens.

show abstract

Section: Resultsmentioning

confidence: 99%

Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis

Tan

Qiu

Zhu

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Wang et al suggested that Chinese Han people with rs1799782 TT/CT genotype of XRCC1 gene may have increased risk of developing colorectal cancer [8]. Some previous studies suggested that XRCC1 rs1799782 polymorphism was associated with the objective response rate (ORR) of platinum-based chemotherapy [9][10][11][12][13][14][15][16][17][18][19][20][21]. However, the results were not coincident.…”

Section: Introductionmentioning

confidence: 63%

XRCC1 rs1799782 polymorphism and objective response rate in NSCLC patients treated with platinum-based chemotherapy

Wang¹,

Du²,

Wang³

et al. 2018

biomedicalresearch

View full text Add to dashboard Cite

show abstract

“…For example, the Gln allele was associated with poorer survival in the study of Wu et al, [303] but exhibited no effect on pa ent survival in Qiu et al, [304] and Zhang et al, [305].…”

Section: Individual Repair Capacity and Eligibility For Different An mentioning

confidence: 94%

“…Carriership of the XPD 312Asn allele in pa ents with non-small cell lung cancer may confer poorer response to pla num-based regimens and shorter survival than the Asp312 variant [304,305,309]. A composite XPD haplotype made of Asn at codon 312 and Gln at codon 751 of the XPD gene is associated with poorer response to pla num-based regimens in advanced non-small cell lung cancer in terms of disease progression a er therapy [310].…”

Section: Individual Repair Capacity and Eligibility For Different An mentioning

confidence: 99%

Individual capacity for detoxification of genotoxic compounds and repair of DNA damage. Commonly used methods for assessment of capacity for DNA repair

Chakarov¹,

Petkova²,

Russev³

2014

Biodiscovery

View full text Add to dashboard Cite

The first part of this paper reviews the major achievements in the rapidly expanding field of research of individual capacity for repair of genotoxic damage. The issues of individual repair capacity are addressed from mul ple sides, analyzing the impact of the heritable components of the capacity for detoxifica on of genotoxic compounds, on the one hand (determining the risk for occurrence of DNA damage) and of the capacity for repair of DNA damage (when it has already occurred), on the other hand. The role of the capacity for repair of damage to DNA is discussed in the cons tu on of the risk for development of disease (mainly cancer, but also other common diseases and condi ons, such as diabetes, atherosclerosis and cardiovascular disease) and as a major factor in the outcomes of genotoxic therapies (eligibility for therapy with specific agents, risk for severe adverse effects, post-therapeu c survival rates, etc.). The paper contains an extensive list of biomarkers (mainly DNA polymorphisms, but also enzymes and other phenotypic markers, such as markers of the capacity for self-renewal of cell popula ons) that may be poten ally applicable in the assessment of the risk for carcinogenesis or for development other types of human disease.The second part of the paper provides a brief glimpse of the basic methodology used to obtain experimental results in assessment of the efficiency of DNA repair in living cells for research and diagnos c purposes.Cita on: Chakarov S, Petkova R, Russev GCh. Individual capacity for detoxifica on of genotoxic compounds and repair of DNA damage. Commonly used methods for assessment of capacity for DNA repair.

show abstract

Pharmacogenetics of DNA repair gene polymorphisms in non-small-cell lung carcinoma patients on platinum-based chemotherapy

Cited by 23 publications

References 23 publications

Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis

Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis

XRCC1 rs1799782 polymorphism and objective response rate in NSCLC patients treated with platinum-based chemotherapy

Individual capacity for detoxification of genotoxic compounds and repair of DNA damage. Commonly used methods for assessment of capacity for DNA repair

Contact Info

Product

Resources

About